These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2883155)

  • 1. Virulence of Entamoeba histolytica correlates with the capacity to develop complement resistance.
    Mogyoros M; Calef E; Gitler C
    Isr J Med Sci; 1986 Dec; 22(12):915-7. PubMed ID: 2883155
    [No Abstract]   [Full Text] [Related]  

  • 2. [Activity of the alternative complement pathway by various axenic strains of Entamoeba histolytica].
    Capin NR; Capin R; Zamacona G; Ortiz-Ortiz L
    Arch Invest Med (Mex); 1978; 9 Suppl 1():291-6. PubMed ID: 211963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of complement resistance in cloned pathogenic Entamoeba histolytica.
    Hamelmann C; Foerster B; Burchard GD; Shetty N; Horstmann RD
    Parasite Immunol; 1993 Apr; 15(4):223-8. PubMed ID: 8506118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD59 (protectin) molecule, resistance to complement, and virulence of Entamoeba histolytica.
    Flores-Romo L; Tsutsumi V; Estrada-García T; Shibayama M; Aubry JP; Bacon KB; Martínez-Palomo A
    Trans R Soc Trop Med Hyg; 1994; 88(1):116-7. PubMed ID: 7512288
    [No Abstract]   [Full Text] [Related]  

  • 5. Enhancement of virulence of Entamoeba histolytica by in vitro liver treatment.
    Bhol KC; Mukherjee RM; Banerjee M; Maitra TK; Jalan KN
    Ann Trop Med Parasitol; 1991 Jun; 85(3):341-4. PubMed ID: 1746984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The mechanism of natural resistance in the rat to Entamoeba histolytica].
    Pérez-Tamayo R; Becker I; Martínez RD; Olivos A; Montfort I; Pérez-Montfort R
    Arch Invest Med (Mex); 1990; 21 Suppl 1():157-61. PubMed ID: 2136481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement sensitivity of Entamoeba histolytica and various nonpathogenic amoeba species.
    Förster B; Ebert F; Horstmann RD
    Trop Med Parasitol; 1994 Dec; 45(4):355-6. PubMed ID: 7716404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Virulence and surface properties of various axenic strains of Entamoeba histolytica].
    Orozco-Orozco ME; Martínez-Palomo A; Guarneros G
    Arch Invest Med (Mex); 1980; 11(1 Suppl):153-7. PubMed ID: 6258510
    [No Abstract]   [Full Text] [Related]  

  • 9. Interaction of pathogenic and nonpathogenic Entamoeba histolytica with human complement.
    Reed SL; Gault M; Gillin FD; Gigli I; Braude AI; Curd JG; Sargeaunt PG
    Arch Invest Med (Mex); 1987; 18(2):141-9. PubMed ID: 2889433
    [No Abstract]   [Full Text] [Related]  

  • 10. Loss of susceptibility to complement lysis in Entamoeba histolytica HM1 by treatment with human serum.
    Calderon J; Tovar R
    Immunology; 1986 Jul; 58(3):467-71. PubMed ID: 2874111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virulence of Entamoeba histolytica upon continuous axenic cultivation.
    Mattern CF; Keister DB; Natovitz PC
    Arch Invest Med (Mex); 1982; 13 Suppl 3():185-90. PubMed ID: 6295309
    [No Abstract]   [Full Text] [Related]  

  • 12. Virulence of strains of Entamoeba histolytica to rats and the effect of cholesterol, rat caecal and hamster liver passage on the virulence of non-invasive strains.
    Singh BN; Srivastava RV; Dutta GP
    Indian J Exp Biol; 1971 Jan; 9(1):21-7. PubMed ID: 4326108
    [No Abstract]   [Full Text] [Related]  

  • 13. Loss of susceptibility to antibody and complement mediated lysis in E. histolytica.
    Calderon J; Tovar-Gallegos R
    Arch Invest Med (Mex); 1980; 11(1 Suppl):241-4. PubMed ID: 6258517
    [No Abstract]   [Full Text] [Related]  

  • 14. Entamoeba histolytica: differences in phagosome acidification and degradation between attenuated and virulent strains.
    Mitra BN; Kobayashi S; Saito-Nakano Y; Nozaki T
    Exp Parasitol; 2006 Sep; 114(1):57-61. PubMed ID: 16546173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to lysis by human serum of pathogenic Entamoeba histolytica.
    Reed SL; Sargeaunt PG; Braude AI
    Trans R Soc Trop Med Hyg; 1983; 77(2):248-53. PubMed ID: 6306876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysis of pathogenic and nonpathogenic Entamoeba histolytica by human complement: methodological analysis.
    Hamelmann C; Foerster B; Burchard GD; Horstmann RD
    Parasite Immunol; 1992 Jan; 14(1):23-35. PubMed ID: 1557228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the preservation and enhancement of the virulence of some strains of Entamoeba histolytica in axenic and monoxenic cultures.
    Gold D; Norman L
    J Parasitol; 1979 Dec; 65(6):970-2. PubMed ID: 232158
    [No Abstract]   [Full Text] [Related]  

  • 18. Isolation and maintenance of a strain of Entamoeba histolytica Schaudinn, 1903 and the possibility of its utilization in screening of drugs.
    Chaia G; da Silva EF; Vilela CC; Chiari L
    Rev Inst Med Trop Sao Paulo; 1977; 19(3):195-201. PubMed ID: 203016
    [No Abstract]   [Full Text] [Related]  

  • 19. The problem of pathogenicity in parasitic entamoeba.
    Bos HJ
    Acta Leiden; 1973; 40():5-111. PubMed ID: 4356964
    [No Abstract]   [Full Text] [Related]  

  • 20. Lysozyme and complement-dependent lysis of Entamoeba histolytica. Inhibition by leupeptin.
    Mogyoros M; Fishelson Z; Gitler C
    Isr J Med Sci; 1986 Dec; 22(12):918-20. PubMed ID: 2883156
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.